Ftse Mib
33.746,66
-1,60%
DAX
17.932,17
-1,10%
S&P 500
5.026,72
-0,18%
NASDAQ Composite
15.636,84
-0,13%
Bitcoin
57.345,00
-5,37%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Esperion Therapeutics Inc (ESPR) Esperion Therapeutics Inc (ESPR) Notizie

Esperion Therapeutics Inc

ESPR
1,96
-0,01 (-0,51%)
Ultimo aggiornamento: 16:35:16
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
29/4/202414:00GLOBEEsperion to Participate in Upcoming May Investor Conferences
23/4/202414:00GLOBEEsperion to Report First Quarter 2024 Financial Results on..
07/4/202420:45GLOBEEsperion Presents Important New Data from CLEAR Outcomes at..
01/4/202414:00GLOBEEsperion to Ring Nasdaq Opening Bell Today, April 1, 2024
26/3/202413:00GLOBEEsperion to Participate in 23rd Annual Needham Virtual..
25/3/202421:00GLOBEEsperion Announces Data from CLEAR Outcomes Sub-Groups as..
22/3/202423:26BWU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL®..
22/3/202420:10GLOBEU.S. FDA Approves Broad New Labels for NEXLETOL® and..
22/3/202416:04GLOBECHMP Issues Positive Opinions For Both Bempedoic Acid And..
27/2/202415:19EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202413:23EDGAR2Form 8-K - Current report
27/2/202412:00GLOBEEsperion Reports Fourth Quarter and Full Year 2023 Financial..
16/2/202422:30GLOBEEsperion Announces Inducement Grants Under NASDAQ Listing..
14/2/202420:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202416:50EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202414:42EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202412:11EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202414:00GLOBEEsperion to Report Fourth Quarter and Full Year 2023..
01/2/202420:00GLOBERFK, Esperion Therapeutics Announce 2024 Promotional..
23/1/202422:00GLOBEEsperion Announces Closing of Public Offering of Common..
22/1/202412:10EDGAR2Form 8-K - Current report
22/1/202412:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/1/202403:15GLOBEEsperion Announces Pricing of $85.1 Million Public Offering..
18/1/202422:03EDGAR2Form 8-K - Current report
18/1/202422:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/1/202422:00GLOBEEsperion Announces Proposed Public Offering of Common Stock
11/1/202422:09EDGAR2Form 8-K - Current report
03/1/202421:15BWEsperion e Daiichi Sankyo Europe annunciano un emendamento..
03/1/202419:54BWEsperion et Daiichi Sankyo Europe annoncent une révision de..
03/1/202416:07BWEsperion und Daiichi Sankyo Europe geben Anpassung ihrer..
03/1/202414:00EDGAR2Form 8-K - Current report
03/1/202413:00GLOBEEsperion and Daiichi Sankyo Europe Announce $125 Million..
18/12/202314:00GLOBEEsperion to Participate in 42nd Annual J.P. Morgan..
13/12/202322:46DJNEsperion Therapeutics' Nexletol, Nexlizet Updates Get FDA..
13/12/202322:00GLOBEU.S. FDA Updates LDL-C Lowering Indication for Esperion’s..
13/11/202316:30GLOBEEsperion Presents CLEAR Outcomes Analysis of Inflammation as..
11/11/202317:00GLOBEPartners Announce TRANSFORM Trial to Evaluate Personalized..
09/11/202322:30GLOBEEsperion Announces Inducement Grants Under NASDAQ Listing..
07/11/202314:52EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:30EDGAR2Form 8-K - Current report
07/11/202312:00GLOBEEsperion Reports Third Quarter 2023 Financial Results
31/10/202313:00GLOBEEsperion to Participate in Jefferies London Healthcare..
24/10/202314:00GLOBEEsperion to Report Third Quarter 2023 Financial Results on..
05/10/202315:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
21/9/202323:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202321:22EDGAR2Form 144 - Report of proposed sale of securities
12/9/202316:15GLOBEAmerican College of Cardiology Program to Increase..
28/8/202314:00GLOBEEsperion to Participate in H.C. Wainwright 25th Annual..
26/8/202317:00GLOBEEsperion Presents Two CLEAR Outcomes Study Late-Breakers at..
24/8/202315:29EDGAR2Form S-8 - Securities to be offered to employees in employee..
Apertura: 1,99 Min: 1,96 Max: 2,04
Chiusura: 1,97

La tua Cronologia

NASDAQ
ESPR
Esperion Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network